Online Press Release Distribution | EON: Enhanced Online News
  • News
  • Resources
 TARIS Biomedical

TARIS ® to Present at Cowen Health Care Conference

March 12, 2018 08:00 AM Eastern Daylight Time 

LEXINGTON, Mass.--(EON: Enhanced Online News)--TARIS announced that CEO Purnanand Sarma is presenting today, March 12th, at the Cowen and Company 38th Annual Health Care Conference from 8:30-8:55 a.m. ET in the Northeastern Room, 3rd floor at the Boston Marriott Copley Place.

About TARIS Biomedical®

TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new treatments for millions of patients suffering from difficult-to-treat bladder diseases. We are advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed. www.tarisbiomedical.com

Contacts

TARIS Biomedical
Christopher J. Searcy
Chief Business Officer
781-676-7750
csearcy@tarisbio.com

Recent Stories

  • View Press Release
    TARIS Presents Data Demonstrating Significant Local and Systemic Immune Modulation Following Continuous Low-Dose Bladder Delivery of Gemcitabine
    April 16, 2018
    LEXINGTON, Mass.--(EON: Enhanced Online News)--TARIS today presented a late-breaking poster titled “Significant cytotoxic and immunomodulatory effects of continuous low-dose intravesical gemcitabin... more »
  • View Press Release
    TARIS® Announces Late-Breaking Poster Presentation at American Association of Cancer Research Annual Meeting
    April 09, 2018
    LEXINGTON, Mass.--(EON: Enhanced Online News)--TARIS today announced that it will present a late-breaking poster related to TAR-200 (GemRIS™), the company’s lead clinical program in bladder cancer,... more »
  • View Press Release
    U.S. FDA Grants Fast Track Designation to TARIS® for TAR-200 (GemRIS™) in Muscle Invasive Bladder Cancer
    April 03, 2018
    LEXINGTON, Mass.--(EON: Enhanced Online News)--TARIS today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for TAR-200 (GemRIS™) for the treat... more »
More Stories
RSS feed for TARIS Biomedical

 TARIS Biomedical

TARIS Biomedical

  • Opens in new windowWebsite
  • News Feed

Share

  • Facebook
  • Twitter
  • LinkedIn
  • Delicious
  • Reddit
  • StumbleUpon
  • Digg
  • MySpace
  • Newsvine
  • Google Bookmark
  • Yahoo! Bookmark
  • Mixx
  • Propeller
  • Wikio
  • EmailEmail
Tweet
  • EmailEmail
News
EON Online Press Release
  • Terms of Use
  • Privacy
  • © 2018 Business Wire, Inc.